Review of the safety and feasibility of rapid infusion of rituximab.
Added to standard chemotherapy, rituximab improved survival in patients with non-Hodgkin's lymphoma; added to fludarabine-based regimens, it improved response and survival in patients with chronic B-cell lymphocytic leukemia.
Atmar
Jill
J
Department of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX.